Our work thus supports that the combination treatment of adagrasib and abemaciclib can offer a therapeutic strategy in NSCLC BM genomically characterized by KRAS-G12C and CDKN2A loss. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.